Article
Oncology
Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang
Summary: This study compared the effectiveness of nivolumab and regorafenib as second-line therapies for hepatocellular carcinoma patients after sorafenib failure. The results showed similar treatment outcomes between nivolumab and regorafenib, with slightly better response rates in the nivolumab group. Despite differences in treatment-related adverse events, there were no significant disparities in time to progression and overall survival between the two groups.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Chi-Jung Wu, Pei-Chang Lee, Ya-Wen Hung, Chieh-Ju Lee, Chen-Ta Chi, I-Cheng Lee, Ming-Chih Hou, Yi-Hsiang Huang
Summary: This study evaluated the efficacy and safety of lenvatinib plus pembrolizumab for unresectable hepatocellular carcinoma (uHCC) patients. The results showed a high disease control rate (DCR) and no adverse effect on liver function score in both systemic therapy-naive and -experienced uHCC patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Er-Min Gu, Ya-Nan Liu, Lvjun Pan, Yingying Hu, Xuemei Ye, Pingping Luo
Summary: This study developed a high throughput method to quantify sorafenib, regorafenib, cabozantinib and their active metabolites in plasma simultaneously. The method showed good specificity, precision, and accuracy, and was successfully applied to pharmacokinetic study.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Shu Zhao, Minhang Zhou, Peng Wang, Jing Yang, Dong Zhang, Fan Yin, Peng Song
Summary: This retrospective study compared the efficacy and safety of transarterial chemoembolization plus lenvatinib and PD-1 inhibitors with transarterial chemoembolization plus lenvatinib or sorafenib in patients with unresectable hepatocellular carcinoma. The results showed that transarterial chemoembolization plus lenvatinib and PD-1 inhibitor group had significantly improved overall survival and prolonged progression-free survival.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT
(2022)
Article
Gastroenterology & Hepatology
Takeshi Terashima, Tatsuya Yamashita, Noboru Takata, Yasuhito Takeda, Hidenori Kido, Noriho Iida, Masaaki Kitahara, Tetsuro Shimakami, Hajime Takatori, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Summary: Sequential administration of sorafenib followed by regorafenib or lenvatinib is effective against advanced hepatocellular carcinoma, with similar safety profiles observed between sorafenib and regorafenib but differences in adverse events and anti-tumor effects between sorafenib and lenvatinib. The results provide insights for selecting sequential therapy for patients with advanced HCC.
HEPATOLOGY RESEARCH
(2021)
Article
Oncology
Yongkang Xu, Shumin Fu, Kai Shang, Jiayu Zeng, Ye Mao
Summary: This study compared the efficacy of PD-1 inhibitors combined with lenvatinib (PL) and combined with regorafenib (PR) in patients with advanced hepatocellular carcinoma (HCC). The results showed that the overall response rate and disease control rate were higher in the PL group than in the PR group, but there was no significant difference in median progression-free survival and overall survival between the two groups. The most common treatment-related adverse events were hand-foot skin reaction, hypertension, and hypothyroidism.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Nabil F. Saba, Conor E. Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca, Mihir Patel, Nicole C. Schmitt, William Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung
Summary: PD-1 therapy is standard treatment for recurrent metastatic head and neck squamous cell carcinoma. The combination of Pembrolizumab and Cabozantinib shows promising clinical activity. Further research is needed.
Article
Pharmacology & Pharmacy
Alessandro Rizzo, Vincenzo Dadduzio, Angela Dalia Ricci, Francesco Massari, Alessandro Di Federico, Gennaro Gadaleta-Caldarola, Giovanni Brandi
Summary: The paper reviews the combination of lenvatinib plus pembrolizumab for advanced HCC treatment, emphasizing the potential benefits and future treatment directions. Expert opinion suggests that the landscape of new agents and combinations is expanding positively based on promising results of early phase clinical trials.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2022)
Article
Pharmacology & Pharmacy
Shun Zhang, Yixin Wang, Yifan Cao, Jin Wu, Zubin Zhang, Haigang Ren, Xiaohui Xu, Elena Kaznacheyeva, Qing Li, Guanghui Wang
Summary: This study found that sorafenib and regorafenib induce cell death in hepatocellular carcinoma by damaging mitochondria, and mitophagy can alleviate this cell death. Inhibiting autophagy or mitochondrial fission can aggravate the cell death caused by these drugs. Additionally, knocking down the protein PINK1 can enhance the inhibitory effects of sorafenib and regorafenib on hepatocellular carcinoma.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Khuloud Bajbouj, Rizwan Qaisar, Mohammed A. Alshura, Zeinab Ibrahim, Mohamad B. Alebaji, Amenah W. Al Ani, Hanadi M. Janajrah, Mariah M. Bilalaga, Abdelrahman Omara, Rebal S. Abou Assaleh, Maha M. Saber-Ayad, Adel B. Elmoselhi
Summary: This study reports for the first time the synergistic anti-angiogenic potential of combination therapy with Lenvatinib and Regorafenib in breast cancer, showing their therapeutic potential in aggressive types. Further studies are needed to confirm and explore this therapeutic approach.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
T. K. Choueiri, T. Powles, M. Burotto, B. Escudier, M. T. Bourlon, B. Zurawski, V. M. Oyervides Juarez, J. J. Hsieh, U. Basso, A. Y. Shah, C. Suarez, A. Hamzaj, J. C. Goh, C. Barrios, M. Richardet, C. Porta, R. Kowalyszyn, J. P. Feregrino, J. Zolnierek, D. Pook, E. R. Kessler, Y. Tomita, R. Mizuno, J. Bedke, J. Zhang, M. A. Maurer, B. Simsek, F. Ejzykowicz, G. M. Schwab, A. B. Apolo, R. J. Motzer
Summary: The study demonstrates that nivolumab plus cabozantinib has significant advantages over sunitinib in the treatment of previously untreated advanced renal-cell carcinoma, including progression-free survival, overall survival, and likelihood of response.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Zichan Dai, Xiaohan Wang, Rangxin Peng, Binghui Zhang, Qi Han, Jie Lin, Jichuang Wang, Junjin Lin, Mingting Jiang, Hekun Liu, Tae Ho Lee, Kun Ping Lu, Min Zheng
Summary: Sorafenib and regorafenib are hindered in their efficacy against HCC by induced IL-6Rα expression, which promotes drug resistance through ATF3-mediated up-regulation. Targeting IL-6Rα may serve as a novel therapeutic strategy to enhance sorafenib/regorafenib efficacy for advanced HCC treatment.
Review
Biochemistry & Molecular Biology
Michael C. Stark, Anna M. Joubert, Michelle H. Visagie
Summary: Immune checkpoint inhibitors (ICIs) are effective immunotherapy agents that can overcome the immunosuppressive effects exerted by tumorigenic cells, specifically targeting the PD-1/PD-L1 immune checkpoint. However, the high cost of ICIs like pembrolizumab and nivolumab limits their accessibility in LMICs. Therefore, developing cost-effective biomanufacturing platforms is crucial for expanding access to these therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Robert Motzer, Boris Alekseev, Sun-Young Rha, Camillo Porta, Masatoshi Eto, Thomas Powles, Viktor Gruenwald, Thomas E. Hutson, Evgeny Kopyltsov, Maria J. Mendez-Vidal, Vadim Kozlov, Anna Alyasova, Sung-Hoo Hong, Anil Kapoor, Teresa Alonso Gordoa, Jaime R. Merchan, Eric Winquist, Pablo Maroto, Jeffrey C. Goh, Miso Kim, Howard Gurney, Vijay Patel, Avivit Peer, Giuseppe Procopio, Toshio Takagi, Bohuslav Melichar, Frederic Rolland, Ugo De Giorgi, Shirley Wong, Jens Bedke, Manuela Schmidinger, Corina E. Dutcus, Alan D. Smith, Lea Dutta, Kalgi Mody, Rodolfo F. Perini, Dongyuan Xing, Toni K. Choueiri
Summary: The study demonstrated that the combination of lenvatinib with pembrolizumab led to significantly longer progression-free survival and overall survival than sunitinib, while the combination of lenvatinib with everolimus showed longer progression-free survival but not overall survival compared to sunitinib. Adverse events were more frequent in patients receiving lenvatinib-based treatments.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Pharmacology & Pharmacy
C. Ventura, M. Junco, F. X. Santiago Valtierra, M. Gooz, Y. Zhiwei, D. M. Townsend, P. M. Woster, E. N. Maldonado
Summary: It is found that small molecules targeting VDAC, such as X1 and SC18, have a synergistic effect with sorafenib, regorafenib, or lenvatinib to inhibit proliferation and induce death in hepatocarcinoma cells. These results suggest that small molecules targeting VDAC could be a potential new class of drugs for liver cancer treatment.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2023)
